Spray-Congealing and Wet-Sieving as Alternative Processes for Engineering of Inhalation Carrier Particles: Comparison of Surface Properties, Blending and In Vitro Performance.
Administration, Inhalation
Anti-Asthmatic Agents
/ administration & dosage
Beclomethasone
/ administration & dosage
Chemical Engineering
/ methods
Chemistry, Pharmaceutical
/ methods
Drug Carriers
/ administration & dosage
Dry Powder Inhalers
/ methods
Mannitol
/ administration & dosage
Nanoparticles
/ administration & dosage
Particle Size
Surface Properties
D-mannitol
dry powder inhaler
particle engineering
spray-congealing
wet-sieving
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
19
03
2021
accepted:
12
05
2021
pubmed:
12
6
2021
medline:
15
12
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Traditionally, α-lactose monohydrate is the carrier of choice in dry powder inhaler (DPI) formulations. Nonetheless, other sugars, such as D-mannitol, have emerged as potential alternatives. Herein, we explored different particle engineering processes to produce D-mannitol carriers for inhaled delivery. Wet-sieving and spray-congealing were employed as innovative techniques to evaluate the impact of engineering on the particle properties of D-mannitol. To that end, the resulting powders were characterized concerning their solid-state, micromeritics and flowability. Afterwards, the engineered carrier particles were blended with inhalable size beclomethasone dipropionate to form low dose (1 wt%) DPI formulations. The in vitro aerosolization performance was evaluated using the NEXThaler®, a reservoir multi-dose device. Wet-sieving generated D-mannitol particles with a narrow particle size distribution and spray-congealing free-flowing spherical particles. The more uniform pumice particles with deep voids and clefts of wet-sieved D-mannitol (Pearl300_WS) were beneficial to drug aerosolization, only when used in combination with a ternary agent (10 wt% of 'Preblend'). When compared to the starting material, the spray-congealed D-mannitol has shown to be promising in terms of the relative increase of the fine particle fraction of the drug (around 100%), when used without the addition of ternary agents. The wet-sieving process and the related aerosolization performance are strongly dependent on the topography and structure of the starting material. Spray-congealing, has shown to be a potential process for generating smooth spherical particles of D-mannitol that enhance the in vitro aerosolization performance in binary blends of the carrier with a low drug dose.
Identifiants
pubmed: 34114162
doi: 10.1007/s11095-021-03061-5
pii: 10.1007/s11095-021-03061-5
pmc: PMC8217042
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Drug Carriers
0
Mannitol
3OWL53L36A
Beclomethasone
KGZ1SLC28Z
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1107-1123Références
Int J Pharm. 2008 Feb 4;348(1-2):10-7
pubmed: 17689898
Int J Pharm. 2019 Feb 25;557:342-353
pubmed: 30599227
Pharm Res. 2006 Aug;23(8):1665-74
pubmed: 16845584
Int J Pharm. 2015 Jan 15;478(1):53-59
pubmed: 25448567
AAPS PharmSciTech. 2013 Sep;14(3):1158-68
pubmed: 23897035
Eur J Pharm Biopharm. 2012 Sep;82(1):194-204
pubmed: 22595133
Eur J Pharm Biopharm. 2015 Oct;96:291-303
pubmed: 26275831
Drug Dev Ind Pharm. 2009 Aug;35(8):904-16
pubmed: 19466888
Int J Pharm. 2012 May 10;427(2):224-33
pubmed: 22349053
J Pharm Sci. 2000 Apr;89(4):457-68
pubmed: 10737907
Int J Pharm. 2011 Jul 15;413(1-2):93-102
pubmed: 21540087
Int J Pharm. 2020 Mar 15;577:118901
pubmed: 31846726
J Pharm Sci. 2005 May;94(5):1004-12
pubmed: 15793798
Int J Pharm. 2019 Apr 20;561:148-160
pubmed: 30825556
Curr Drug Deliv. 2019;16(3):180-194
pubmed: 30360739
Curr Pharm Des. 2015;21(40):5900-14
pubmed: 26446471
AAPS PharmSciTech. 2014 Dec;15(6):1417-28
pubmed: 24962007
Int J Pharm. 2018 Jan 15;535(1-2):59-67
pubmed: 29100914
Int J Pharm. 2017 May 30;524(1-2):351-363
pubmed: 28347847
Int J Pharm. 2008 Sep 1;361(1-2):131-40
pubmed: 18617338
Int J Pharm. 2006 Feb 17;309(1-2):51-9
pubmed: 16377105
Int J Pharm. 2020 Aug 30;586:119592
pubmed: 32622814
Drug Discov Today. 2014 May;19(5):618-26
pubmed: 24269834
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):167-78
pubmed: 26355743
PLoS One. 2014 Jan 28;9(1):e87825
pubmed: 24489969
Int J Pharm. 2007 Apr 4;334(1-2):103-14
pubmed: 17110062
Int J Pharm. 2020 Dec 15;591:120014
pubmed: 33122114